Liquid biopsy offers a potential alternative to tissue biopsy for detection of genetic alterations in cancer, and it has been introduced into clinical practice to detect the tyrosine kinase inhibitor (TKI) resistance-conferring T790M mutation of epidermal growth factor receptor (EGFR) in patients with non-small-cell lung cancer (NSCLC).
| INTRODUC TI ON
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) show marked efficacy for treatment of non-small-cell lung cancer (NSCLC) positive for activating mutations of EGFR. [1] [2] [3] [4] [5] [6] [7] Isolation of circulating cell-free DNA (cfDNA) from blood samples as a liquid biopsy can be carried out in cancer patients in a noninvasive and repetitive way, with analysis of the cfDNA having the potential to provide insight into the extent of intratumoral heterogeneity. 8, 9 Such an approach has been introduced into clinical practice to detect activating mutations or the TKI resistance-conferring T790M mutation of EGFR in patients with NSCLC. [10] [11] [12] [13] [14] [15] [16] Monitoring of cfDNA by digital PCR (dPCR) has been shown to be informative for prediction of EGFR-TKI efficacy, whereas that by next-generation sequencing (NGS) has the potential to identify mechanisms of treatment resistance. 16 Liquid biopsy thus offers a promising alternative to tissue biopsy both for the detection of genetic alterations that can inform the selection of corresponding targeted drugs and for exploration of mechanisms of resistance to such drugs.
Third-generation EGFR-TKI osimertinib prolonged progressionfree survival (PFS) compared with platinum chemotherapy plus pemetrexed in patients with NSCLC positive for activating mutations of EGFR who acquired the T790M mutation and whose disease progressed during previous EGFR-TKI therapy. 17 Detection of T790M at the time of progression is therefore essential for determination of the optimal subsequent treatment for this patient population. Given that tumor biopsy is invasive and not always feasible, liquid biopsy could be an important alternative for such analysis. Analysis by NGS has the potential to detect several genetic alterations such as TP53 mutations that exist together with EGFR mutations, but little is known of how such coexisting genetic alterations affect clinical outcome. 18, 19 We previously showed that monitoring of cfDNA by dPCR is informative for prediction of the efficacy of the second-generation EGFR-TKI afatinib in NSCLC patients positive for EGFR activating mutations and that allele frequency for somatic mutations in cfDNA determined by NGS changed concordantly during afatinib treatment with the number of EGFR mutant alleles determined by dPCR. 16 In the present study, both tumor and plasma samples were prospectively collected from these patients at the time of treatment failure and were examined for genetic alterations with both dPCR and NGS in order to investigate mechanisms of resistance to afatinib treatment.
| MATERIAL S AND ME THODS

| Study design and participants
Between 20 May and 25 November 2014, a total of 35 patients who had not previously been treated with EGFR-TKI were enrolled in the present study from 10 institutions across Japan. The patients had histologically or cytologically confirmed adenocarcinoma of the lung at stage IIIB or IV or postoperative recurrence, and they were positive for a common activating mutation of EGFR (an exon 19 deletion [Ex19del] or the L858R point mutation). They received a single daily dose of afatinib at a starting dose of 40 mg until development of progressive disease (PD) or intolerable adverse events, or until withdrawal of consent. Detailed information regarding study design as well as the baseline demographics and clinical characteristics of the patients has been presented previously. 16 All patients provided written informed consent, and the study was carried out in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of each institution.
| Sample collection
Tumor and plasma samples were collected before afatinib treatment and after treatment failure with disease progression (systemic PD).
Blood samples (14 mL) were collected in tubes containing EDTA of the number of T790M alleles to that of activating mutation alleles (T/A ratio) improved the specificity of plasma analysis to 100% for both dPCR and NGS without a reduction in sensitivity. Although several afatinib resistance mechanisms other than T790M-including copy number gain of NRAS or MET-were identified in tumor samples, the corresponding genetic alterations were not detected in plasma. TP53 mutations were frequently identified in plasma and tumor samples, with most such mutations also having been detected before afatinib treatment. The presence of de novo TP53 mutations was associated with reduced progression-free survival.
Quantitation of T790M in plasma is thus a clinically relevant approach to determine the T790M status of tumors. In addition, genetic alterations coexisting with EGFR mutations can affect the efficacy of EGFR-TKI treatment.
K E Y W O R D S
afatinib, circulating tumor DNA, digital PCR, next-generation sequencing, resistance mechanism (disodium salt) and were centrifuged at 1400 g for 10 minutes at room temperature within 1 hour of collection. The supernatant was stored at −80°C until analysis. Detailed protocols for isolation of DNA from tumor samples and from blood samples (cfDNA) are provided in Doc. S1.
| Scorpion amplification-refractory mutation system
We carried out allele-specific PCR analysis by Scorpion ARMS (amplification-refractory mutation system) with a Therascreen EGFR RGQ PCR Kit (QIAGEN K.K., Tokyo, Japan) as a conventional method to detect activating and T790M mutations of EGFR in tumor samples. Details are provided in Doc. S1.
| Nanofluidic dPCR analysis
The principles and details of the nanofluidic dPCR system (BioMark HD System; Fluidigm, South San Francisco, CA, USA) as carried out with the Fluidigm digital chip have been described previously. 16, 20 ARMS was carried out in each reaction chamber targeting either the control region (exon 2), activating mutations (Ex19del or L858R), or T790M of EGFR in both tumor and plasma samples. We carried out duplicate assays (two panels) for detection of each target allele.
Tumor samples collected from 15 NSCLC patients without EGFR activating mutations were analyzed to determine the cutoff for T790M positivity in tumor samples (Table S1 ). The number of positive signals observed in the T790M reaction panels increased with the estimated number of control alleles applied ( Figure S1 ). A tumor sample was thus considered positive for T790M if the ratio of the number of positive signals in the T790M reaction to the number of control alleles was ≥0.54 (mean + 3 SD; Table S1 ). The concentration of cfDNA in plasma samples collected either from five patients with NSCLC negative for EGFR activating mutations or from five healthy donors was much lower than that of tumor DNA, with the result that essentially no signal for T790M was detected with the plasma samples (Table S2) . We therefore set a cutoff for T790M positivity in plasma samples different from that in tumor samples.
On the basis of this analysis, plasma samples were thus considered positive for T790M if the ratio of the number of positive signals in the T790M reaction to the number of control alleles was ≥0.17
(mean + 3 SD).
| Next-generation sequencing analysis
Tumor and cfDNA samples were analyzed with NGS panels for mu- 
| Statistical analysis
Details are provided in Doc. S1.
| RE SULTS
| Patient population and clinical outcomes
We have previously indicated marked antitumor activity and tolerable toxicity of afatinib treatment in a prospective study. 16 We updated the data at a median follow-up time of 15.8 months (range, 0.9-41.7 months) as a result of an increase in events related to PFS. Figure S2C ), with the value for patients with an Ex19del mutation being slightly greater than that for those with the L858R mutation (17.9 vs 12.8 months, P = 0.87; Figure S2D ). (Table S3 ). In the case of the two patients for whom EGFR activating mutations were not detected in tumor samples by dPCR, such a mutation was also not detected by NGS in one patient (patient #12). Given that an EGFR activating mutation was detected in the tumor sample obtained from this patient before afatinib treatment, the mutation may have disappeared during treatment or the tumor sampling sites may have differed between before and after failure of afatinib treatment (intratumoral heterogeneity). An activating mutation was not detected by dPCR in patient #7 because the mutation type (Ex19del, p.S752_I759 del) is not recognizable by dPCR. The T790M mutation of EGFR was detected in nine (50.0%), 10 (55.6%), and eight (44.4%) of the 18 tumor samples obtained at the time of systemic PD development by dPCR, NGS, and ARMS, respectively (Table 1, Table S3 ).
Among the 23 plasma samples obtained at the time of systemic PD development, EGFR activating mutations were identified in 16 (69.6%) and 14 (60.9%) samples by dPCR and NGS, respectively (Table S3 ). The T790M mutation was detected in 13 (56.5%) and 10 (43.5%) of these 23 samples by dPCR and NGS, respectively (Table 1, Table S3 ). Discordant results among dPCR, NGS, and ARMS for detection of T790M in tumor or plasma samples were obtained for eight (32%) of 25 patients (Table 1 ). In the case of the 16 patients for whom tumor and plasma samples were both available, sensitivity and specificity for detection of T790M in plasma (relative to that in tumor samples with the conventional method of ARMS) were 83.3%
and 70.0%, respectively, for dPCR and 50.0% and 70.0%, respectively, for NGS ( Figure 1A ).
| Assessment of the T/A ratio for quantitative evaluation of T790M status in tumor and plasma samples at the time of systemic PD development
Given that a high ratio of the number of T790M alleles to that of activating mutation alleles (T/A ratio) in tumor or plasma samples has been associated with resistance to first-generation EGFR-TKI and with a high efficacy of third-generation EGFR-TKI, 13, 21, 22 we calculated the T/A ratio for both dPCR and NGS and thereby quantitatively evaluated the T790M status of each sample (Tables 2, 3, S4, and S5). We determined that cutoffs for the T/A ratio of 5.0% in dPCR and of 10.0% in NGS allowed positivity for T790M evaluated by these techniques to fully match in both tumor ( Figure S3 ) and TA B L E 1 Concordance of T790M positivity between tumor and plasma samples as evaluated by dPCR, NGS, and ARMS (n = which is close to the cutoff value of 7.40. We therefore considered this patient to be positive for T790M. On the basis of the various results, 13 (52.0%) of the 25 patients were deemed positive for T790M (Table 4 ).
| Next-generation sequencing analysis of somatic alterations other than T790M of EGFR
Among the 18 tumor samples obtained at the time of systemic PD development, the T790M mutation of EGFR alone (n = 7), copy number gain (CNG) of NRAS (n = 1), CNG of MET (n = 1), CNG of EGFR plus T790M (n = 1), and CNG and E545K of PIK3CA plus T790M of EGFR (n = 1) were identified by NGS as putative mechanisms of resistance to afatinib (Table 3) . CNG of MET was also detected in the corresponding tumor sample obtained before treatment, with this patient experiencing systemic PD immediately after afatinib initiation. Putative resistance mechanisms other than T790M were not identified by NGS in plasma samples obtained at the time of systemic PD. Mechanisms of resistance to afatinib including the data for plasma analysis of T790M are summarized in Table 4 and Figure 2 .
Mutations of TP53 were identified in tumor or plasma samples obtained at systemic PD from 10 (40%) of the 25 patients with such samples available (Table 3) .
| Survival analysis according to TP53 mutation and EGFR T790M status
We previously identified a total of 45 mutations in tumor samples collected before afatinib treatment from 32 patients with such samples available, 16 with TP53 mutations being found in 11 (34.4%) of these patients (Table S6) Figure 3B ). Although the difference also did not achieve statistical significance, median time to systemic PD was substantially longer in patients with T790M as based on the T/A ratio than in those without it (17.9 vs 10.9 months, P = 0.18; Figure 3C ).
| D ISCUSS I ON
In the present study, both tumor and plasma samples were prospectively collected from patients who experienced failure of afatinib treatment and were analyzed by dPCR and NGS. Without application of the T/A ratio, the T790M mutation of EGFR was positive in nine (50.0%), 10 (55.6%), and eight (44.4%) of 18 tumor samples obtained at the time of systemic PD development as evaluated by dPCR, NGS, and ARMS, respectively, and it was positive in 13 (56.5%) and 10 (43.5%) of 23 plasma samples by dPCR and NGS, respectively (Table 1) . With evaluation of tumor samples by the allele-specific PCR method (ARMS) as reference, the sensitivity and specificity of plasma analysis for T790M were 83.3% and 70.0%, respectively, for dPCR and 50.0% and 70.0%, respectively, for NGS ( Figure 1A ), values consistent with those reported in previous studies.
13,14
F I G U R E 1 Sensitivity and specificity of digital PCR (dPCR) and next-generation sequencing (NGS) for the detection of T790M in plasma samples compared with analysis of tumor samples. Positivity for T790M was determined without the use of the T/A ratio (A) or on the basis of the T/A ratio for plasma and tumor analysis (B). Asterisk indicates that two patients were excluded from the analysis either because the activating mutation (p.S752_I759 del) is not recognizable by dPCR (patient #7) or because the activating mutation seemed to disappear during afatinib treatment (patient #12). T/A ratio, number of T790M alleles to that of activating mutation alleles Table S3 ). These detection rates for T790M are much higher than those previously reported for tumor samples collected from patients who experienced resistance to first-or second-generation EGFR-TKI. [23] [24] [25] [26] Although such a high frequency of T790M might be the result of selection bias due to the small number of samples, we considered the possibility that highly sensitive methods such as dPCR and NGS might detect a small population of T790M alleles in cfDNA that is not responsible for resistance to EGFR-TKI and give rise to the low specificity of plasma analysis for the detection of The T/A ratio was not evaluable in this patient (shaded in gray) because the activating mutation seemed to disappear during afatinib treatment. c Patients #7 and #12 were excluded because of NE status. 
(Continues)
with EGFR-TKI. 20, [27] [28] [29] We previously showed that first-generation EGFR-TKI were effective for the treatment of tumors with a low T/A ratio determined by dPCR and that the T/A ratio increased markedly after the acquisition of EGFR-TKI resistance. 20 A high T/A ratio in tumor or plasma samples has also previously been associated with a high treatment efficacy of third-generation EGFR-TKI. 13, 21, 22 These previous data suggest that assessment of the T/A ratio allows more accurate evaluation of the contribution of T790M to resistance to first-or second-generation EGFR-TKI and improves the concordance between liquid biopsy and tumor biopsy for the detection of T790M.
We therefore applied the T/A ratio to determination of T790M positivity in tumor and plasma samples by dPCR and NGS, resulting in an improvement in the specificity of plasma analysis compared with tumor analysis to 100% without a reduction in sensitivity ( Figure 1B ). Amplification of MET and the E545K mutation of PIK3CA have been implicated in resistance to first-generation EGFR-TKI, together accounting for ~5% of patients who acquired resistance to these drugs. 24, 25 Amplification of EGFR concurrent with T790M has been implicated in resistance to the second-generation EGFR-TKI dacomitinib in a preclinical study 33 and was identified in plasma samples obtained from patients who acquired resistance to third-generation EGFR-TKI. 36 Amplification of NRAS has been implicated in resistance to the third-generation EGFR-TKI naquotinib in a preclinical model. 37 These previous data suggest that such genetic alterations constitute resistance mechanisms shared by various generations of EGFR-TKI.
Resistance-related alterations coexisting with T790M of EGFR were identified in two patients of the present study, with such alterations having been implicated in reduced sensitivity to osimertinib. T/A ratios >10.0% are shown in bold. The T/A ratio was set to zero if both activating mutations and T790M were not detected. The EGFR activating mutation detected in a tumor sample obtained before afatinib treatment seemed to disappear in patient #12 (shaded in gray). Somatic alterations that had been identified before afatinib treatment are shown in red. CNG, copy number gain; EGFR, epidermal growth factor receptor; NA, not available; NGS, next-generation sequencing; T/A ratio, number of T790M alleles to that of activating mutation alleles ; *, stop codon.
TA B L E 3 (Continued)
TA The T/A ratio was not evaluable because the activating mutation seemed to disappear during afatinib treatment.
ARMS, amplification-refractory mutation system; CNG, copy number gain; dPCR, digital PCR; NA, not available; ND, not detected; NGS, next-generation sequencing; T/A ratio, number of T790M alleles to that of activating mutation alleles.
Evaluation of alterations coexisting with EGFR T790M is thus im- Mutations of TP53 were frequently identified in plasma samples collected at the time of systemic PD development as well as in tumor samples (Table 3 ). In 9 (90.0%) of 10 patients for whom mutations of TP53 were detected in plasma or tumor samples at systemic PD, the same type of TP53 mutation was also detected in tumor or plasma samples obtained before initiation of afatinib treatment (Table 3) .
Frequency of putative mechanisms of acquired resistance to afatinib among the 25 patients for whom tumor or plasma samples were available at the time of systemic of progressive disease development. CNG, copy number gain; EGFR, epidermal growth factor receptor
NRAS CNG (n = 1) 4%
T790M + EGFR CNG (n = 1) 4%
T790M + PIK3CA CNG + PIK3CA E545K (n = 1) 4% T790M (n = 11) 44% Unknown (n = 10) 40%
F I G U R E 3 Survival analysis according to TP53 or EGFR T790M status. A, Kaplan-Meier plots of progression-free survival (PFS) for the study subjects according to TP53 mutation status in tumor samples obtained before afatinib treatment. B,C, Kaplan-Meier plots of PFS and time to systemic progressive disease (PD) (TSP), respectively, for the study subjects according to T790M status based on the T/A ratio of tumor samples at systemic PD development. Median (m) values for PFS and TSP, and the P value for the difference between each pair of curves as determined with the log-rank test, are indicated. EGFR, epidermal growth factor receptor; T/A ratio, number of T790M alleles to that of activating mutation alleles
Median PFS was significantly shorter in patients whose tumors harbored a TP53 mutation before afatinib treatment than in those whose tumors did not (10.3 vs 15.1 months, P = 0.01; Figure 3A ), consistent with previous findings. 39 All these mutations were located in exons 5-8 of TP53, which encode the DNA-binding domain that recognizes a consensus sequence in the promoters of several genes related to DNA repair and apoptosis. 40, 41 The p53 protein has been shown to enhance gefitinib-induced apoptosis in NSCLC cells by upregulation of FAS, and TP53 mutations reduce sensitivity to EGFR-TKI. 42 , 43 We previously showed that the allele frequency for TP53 mutations and that for EGFR-activating mutations in plasma samples evaluated by NGS changed concordantly during afatinib treatment, with the frequencies declining during the period that afatinib was effective and increasing at disease progression. 16 Quantitative evaluation of T790M will thus be important for assessment of the contribution of this mutation to EGFR-TKI resistance.
Further studies of the mechanisms of resistance to EGFR-TKI and of the pathways that limit the tumor response to these drugs are warranted to overcome the problems associated with both intrinsic and acquired drug resistance. 
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